FUJIFILM (4901) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
12 May, 2026Executive summary
Achieved record highs in revenue, operating income, and net income for FY2025, with revenue up 5.0% year-over-year to ¥3,357.0 billion and net income up 6.0% to ¥276.7 billion, driven by strong performance in Healthcare, Electronics, Imaging, and bio CDMO segments.
Q4 FY2025 revenue rose 6.8% year-over-year to ¥927.3 billion, with net income up 5.0% to ¥83.4 billion.
Comprehensive income surged to ¥580.7 billion, up 131.4% year-over-year, mainly due to significant foreign currency translation gains.
FY2026 guidance targets further record highs, with revenue forecast at ¥3,470.0 billion (+3.4%), operating income at ¥365.0 billion (+4.2%), and net income at ¥280.0 billion (+1.2%).
Financial highlights
FY2025 revenue: ¥3,357.0 billion (+5.0% YoY); operating income: ¥350.2 billion (+6.1% YoY); net income: ¥276.7 billion (+6.0% YoY).
Gross profit margin: 40.8%; operating margin: 10.4%; ROE: 7.7%; ROIC: 5.5%.
EPS for FY2025: ¥229.65 (+¥12.98 YoY); ROE: 7.7%; ROIC: 5.5%.
Overseas sales accounted for 65.2% of total revenue.
Free cash flow was negative ¥144.0 billion due to high capital expenditures.
Outlook and guidance
FY2026 revenue forecast: ¥3,470.0 billion (+3.4% YoY); operating income: ¥365.0 billion (+4.2% YoY); net income: ¥280.0 billion (+1.2% YoY).
Aims for record highs across all key metrics, supported by expansion in Bio CDMO and Semiconductor Materials.
Dividend per share planned at ¥75.0, marking the 17th consecutive annual increase.
Guidance does not factor in potential impacts from energy cost volatility or Middle East tensions; a scenario of crude oil at $100/barrel could reduce operating profit by ¥30–40 billion per quarter.
Free cash flow expected to turn positive as capital expenditures decrease.
Latest events from FUJIFILM
- IP-driven innovation and portfolio transformation fuel growth in healthcare and electronics.4901
Investor Day 202615 Apr 2026 - AI-powered imaging and integrated solutions fuel growth and clinical value in global healthcare.4901
Investor presentation13 Apr 2026 - Record revenue and profit guidance upgrades driven by Electronics and Imaging growth.4901
Q3 20265 Feb 2026 - Aiming for ¥500bn revenue and market leadership in key semiconductor materials by FY2030.4901
Investor Update10 Dec 2025 - Record H1 and Q2 results driven by imaging and bio CDMO growth, with raised revenue guidance.4901
Q2 20266 Nov 2025 - Operating income surged 21% on flat revenue, with Imaging leading growth and tariff risks ahead.4901
Q1 20266 Aug 2025 - Record Q1 growth and raised outlook driven by electronics and imaging.4901
Q1 202513 Jun 2025 - Record revenue and operating income, but net income declined on higher non-operating costs.4901
Q2 202513 Jun 2025 - Record earnings and robust outlook fueled by Electronics and Imaging growth.4901
Q3 20259 Jun 2025